000			02047 a2200553 4500
005			20250514232011.0
264		0	_c20051201
008			200512s 0 0 eng d
022			_a0014-4819
024	7		_a10.1007/s00221-005-2302-1 _2doi
040			_aNLM _beng _cNLM
100	1		_aBové, Jordi
245	0	0	_aNeuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. _h[electronic resource]
260			_bExperimental brain research _cSep 2005
300			_a362-74 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdenosine A2 Receptor Antagonists
650	0	4	_aAnimals
650	0	4	_aCaffeine _xanalogs & derivatives
650	0	4	_aCell Count
650	0	4	_aDynorphins _xbiosynthesis
650	0	4	_aEnkephalins _xbiosynthesis
650	0	4	_aGlobus Pallidus _xphysiology
650	0	4	_aImmunohistochemistry
650	0	4	_aIn Situ Hybridization
650	0	4	_aMale
650	0	4	_aMicroinjections
650	0	4	_aNeostriatum _xphysiology
650	0	4	_aNeural Pathways _xphysiology
650	0	4	_aNeuroprotective Agents
650	0	4	_aOxidopamine _xadministration & dosage
650	0	4	_aParkinson Disease, Secondary _xchemically induced
650	0	4	_aProtein Precursors _xbiosynthesis
650	0	4	_aRNA, Messenger _xbiosynthesis
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReceptor, Adenosine A2A _xbiosynthesis
650	0	4	_aStereotyped Behavior _xdrug effects
650	0	4	_aSubstantia Nigra _xcytology
650	0	4	_aSympatholytics _xadministration & dosage
650	0	4	_aTyrosine 3-Monooxygenase _xmetabolism
700	1		_aSerrats, Jordi
700	1		_aMengod, Guadalupe
700	1		_aCortés, Roser
700	1		_aTolosa, Eduardo
700	1		_aMarin, Concepció
773	0		_tExperimental brain research _gvol. 165 _gno. 3 _gp. 362-74
856	4	0	_uhttps://doi.org/10.1007/s00221-005-2302-1 _zAvailable from publisher's website
999			_c15626779 _d15626779